The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
Authors
Keywords
Atherosclerosis, Insulin resistance, Sodium glucose cotransporter, Type 2 diabetes
Journal
DIABETOLOGIA
Volume 60, Issue 2, Pages 364-376
Publisher
Springer Nature
Online
2016-11-19
DOI
10.1007/s00125-016-4158-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
- (2016) François Briand et al. DIABETES
- Pathophysiology of lipid droplet proteins in liver diseases
- (2016) Rotonya M. Carr et al. EXPERIMENTAL CELL RESEARCH
- The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
- (2015) Volker Vallon Annual Review of Medicine
- Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis
- (2015) Soo Lim et al. ATHEROSCLEROSIS
- Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders
- (2015) Soo Lim et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Repetitive Glucose Spike and Hypoglycaemia on Atherosclerosis and Death Rate in Apo E-Deficient Mice
- (2015) Kenichi Nakajima et al. International Journal of Endocrinology
- Adipokines, diabetes and atherosclerosis: an inflammatory association
- (2015) Leandro C. Freitas Lima et al. Frontiers in Physiology
- Metformin Inhibits Monocyte-to-Macrophage Differentiation via AMPK-Mediated Inhibition of STAT3 Activation: Potential Role in Atherosclerosis
- (2015) Sathish Babu Vasamsetti et al. DIABETES
- Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice
- (2015) Michishige Terasaki et al. PLoS One
- Modulation of adiponectin as a potential therapeutic strategy
- (2014) Soo Lim et al. ATHEROSCLEROSIS
- C-reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells
- (2014) Fang Bian et al. BRITISH JOURNAL OF PHARMACOLOGY
- Impact of MCP -1 in Atherosclerosis
- (2014) Juntang Lin et al. CURRENT PHARMACEUTICAL DESIGN
- Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial
- (2014) Bruce A. Perkins et al. DIABETES CARE
- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
- (2014) A. Liakos et al. DIABETES OBESITY & METABOLISM
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Cardiovascular and hemodynamic effects of glucagon-like peptide-1
- (2014) Adam G. Goodwill et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- Identification of Cardiometabolic Risk: Visceral Adiposity Index Versus Triglyceride/HDL Cholesterol Ratio
- (2013) Martin R. Salazar et al. AMERICAN JOURNAL OF MEDICINE
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis
- (2013) S. Goring et al. DIABETES OBESITY & METABOLISM
- A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
- (2013) E. Ferrannini et al. DIABETES OBESITY & METABOLISM
- Hepatictrans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly
- (2013) Deike Hesse et al. JOURNAL OF LIPID RESEARCH
- Effects of Combining Linagliptin Treatment with BI-38335, A Novel SGLT2 Inhibitor, on Pancreatic Islet Function and Inflammation in db/db Mice
- (2012) L. Chen et al. CURRENT MOLECULAR MEDICINE
- Stress Augments Insulin Resistance and Prothrombotic State: Role of Visceral Adipose-Derived Monocyte Chemoattractant Protein-1
- (2012) Y. Uchida et al. DIABETES
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2012) K. Stenlöf et al. DIABETES OBESITY & METABOLISM
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity
- (2011) K Yamamoto et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effect of S-adenosylmethionine on neointimal formation after balloon injury in obese diabetic rats
- (2011) Soo Lim et al. CARDIOVASCULAR RESEARCH
- Reduced Adipose Tissue Inflammation Represents an Intermediate Cardiometabolic Phenotype in Obesity
- (2011) Melissa G. Farb et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Modulation of lipid droplet size and lipid droplet proteins by trans-10,cis-12 conjugated linoleic acid parallels improvements in hepatic steatosis in obese, insulin-resistant rats
- (2010) Danielle M. Stringer et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
- (2010) Que Liu et al. Cardiovascular Diabetology
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug
- (2009) Iskandar Idris et al. DIABETES OBESITY & METABOLISM
- Adipose Macrophage Infiltration Is Associated With Insulin Resistance and Vascular Endothelial Dysfunction in Obese Subjects
- (2008) Caroline M. Apovian et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes
- (2008) Katerina Papathanassiou et al. ATHEROSCLEROSIS
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More